Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURE study of PEG-Intron maintenance versus supportive care in HIV/HCV coinfected cirrhosis
2005-003876-39Phase 3Terminated
- Sponsor
- Integrated Therapeutics Group
- Start
- Aug 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in hepatitis C virus infection, human immunodeficiency virus infection (HIV) and Cirrhosis (2 arms), sponsored by Integrated Therapeutics Group. Primary endpoint: Efficacy comparison throughout study. Started Aug 2006; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)Cirrhosis
Beyond the preview
Go deeper on 2005-003876-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003876-39.